An Introduction to HIV
HIV infection has been a major global problem since its emergence in 1981. Antiretroviral drugs revolutionized the treatment and prevention of HIV, but adherence and the impact on quality of life are ongoing challenges. New longer-acting treatments have recently been introduced to help address these issues, and evolving treatments with a novel mode-of-action are currently under investigation.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Jeffrey Kwong, ACTHIV 2023: Sexual health in older adults living with HIV, clinical considerations for PrEP, and HIV prevention promotion
Sexual health in the aging process is crucial for healthcare professionals to be educated on due to its significant impact on overall well-being and quality of life for older adults living with HIV. In this interview, we speak with Prof. Jeffrey Kwong (Rutgers School of Nursing, Newark, NJ, USA) to explore the importance of addressing […]
Advancements in HIV Vaccine Development
touchREVIEWS in Infectious Diseases. 2023;2(1):Online ahead of journal publication
Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory adapted strains of HIV were unsuccessful due to their structural dissimilarities to the native HIV […]
Amphotericin B, an oral lipid nanocrystal for cryptococcal meningitis, phase 2 results: David Boulware, ECCMID 2023
Intravenous amphotericin B is a mainstay of treatment in cryptococcal meningitis, in this phase 2 study the efficacy and safety of amphotericin B, a novel, orally absorbed, less-toxic formulation is investigated. It was a pleasure to talk with Prof. David Boulware (University of Minnesota, Minneapolis, USA) to learn more around the prevalence, clinical presentations and […]
Bifast study: efficacy and safety of immediate start of BIC/FTC/TAF after HIV diagnosis: Aws Waleed M. Al-Hayani, ECCMID 2023
After HIV diagnosis, antiretroviral therapy is indicated to be started as early as possible, the phase 4 Bifast study looked at the efficacy and safety of BIC/FTC/TAF when initiated at the first HIV-specialist appointment. In this interview with Dr. Aws Waleed M. Al-Hayani (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) we discuss the controversies surrounding […]
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Nyaradzo Mgodi, CROI 2023: HIV prevention in practice – Unmet needs and clinical evidence for long acting cabotegravir in at-risk populations
Despite significant progress in HIV prevention efforts, unmet needs and challenges remain in at-risk populations. These include issues such as stigma, lack of access to healthcare and prevention services, and implementation of effective prevention strategies. Dr Nyaradzo Mgodi (Zimbabwe University, Zimbabwe) joins touchINFECTIOUS DISEASES to discuss the unmet needs and challenges that remain in at-risk […]
Nyaradzo Mgodi, CROI 2023: Dapivirine vaginal ring in pregnant and breastfeeding Women – Delivery modalities of HIV prevention, highlights from CROI
The dapivirine vaginal ring has been developed as a HIV prevention method for pregnant and breastfeeding women, releasing dapivirine, an antiretroviral drug over a 28-day period to reduce the risk of HIV transmission. This method has shown promising results in clinical trials and could be an important tool for reducing the burden of HIV among […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!